地中海型贫血治疗市场－全球产业规模、份额、趋势、机会、预测：依治疗方法、类型、最终用户、地区和竞争格局划分，2021-2031年

全球地中海贫血治疗市场预计将从 2025 年的 9.2381 亿美元增长到 2031 年的 14.5622 亿美元，复合年增长率为 7.88%。

该领域涵盖的治疗方法包括慢性输血疗法、铁螯合疗法、骨髓移植以及新兴的基因疗法。成长的主要驱动力是全球遗传性血液疾病发生率的上升以及基因编辑技术等根治性干预措施的整合。此外，政府支持的筛检计画的扩展、创新疗法的监管核准以及旨在降低β-地中海贫血患者输血依赖性的强大研发管线的建立，也推动了市场的发展。

儘管取得了这些进展，但新治疗方法的高昂成本以及与长期输血通讯协定相关的复杂后勤保障阻碍了其广泛应用。确保稳定安全的血液供应仍然是许多地区面临的重大挑战。例如，国际地中海贫血联合会预测，到2025年，中低收入国家超过75%的患者将面临血液短缺。这种资源分配上的差距仍然是全球市场进入和公平分配治疗方案的重要障碍。

市场驱动因素

基因编辑疗法的商业化正在从根本上改变全球地中海贫血治疗市场，将治疗重点从慢性疾病管理转向潜在的功能性治癒。这项转变的驱动力在于，针对输血依赖型β-地中海贫血遗传根源的高价值体外基因疗法核准并投入使用，从而获得了显着的市场价值，并在专业医疗机构中占据了重要地位。例如，Bluebird Bio在2024年11月发布的2024年第三季财报中报告称，截至目前，该公司已在其商业化产品组合中为57名患者启动了治疗，其中35名患者接受了β-地中海贫血治疗药物Zintegro的治疗。 Vertex Pharmaceuticals在2024年11月发布的2024年第三季财报中也宣布，其基因编辑疗法Casgevy已累计200万美元的首笔商业收入，进一步印证了该公司在财务上的成熟。

同时，地中海贫血和血红蛋白疾病在全球范围内的日益流行，推动了对创新治疗方法和支持性护理的强劲需求。随着诊断能力的提高和人口结构的变化，需要终身照护的患者人数不断增加，尤其是在遗传特征高度集中的地区。根据国际地中海贫血联盟于2025年1月发布的《全球证据与差距图谱》报告，全球每年约有30万名儿童出生时患有血红蛋白疾病，凸显了开发可扩展治疗方法的迫切性。日益加重的疾病负担要求医疗保健领域进行大量投资，以确保对铁螯合疗法和输血基础设施的基本需求仍然是推动治疗量成长的关键因素，同时基因疗法占据高端市场。

市场挑战

新型基因疗法的高成本是限制全球地中海贫血治疗市场成长的主要阻碍因素。儘管这些先进治疗方法有望治癒地中海贫血，但其定价结构给医疗保险公司和报销体系带来了沉重的经济负担。这种经济压力限制了疗法的普及，许多私人保险公司和公共卫生计画难以承担这些疗法所需的巨额前期费用。因此，监管部门的核准与患者实际获得治疗之间的差距正在扩大，限制了新兴市场和成熟市场製造商的潜在获利能力。

这种经济上的排他性造成了公平获取治疗的巨大障碍，目前的行业价格便印证了这一点。根据国际地中海贫血联合会2025年的报告，已通过核准采集费用基因编辑疗法的平均费用将超过每位患者210万美元。如此高昂的价格障碍实际上使得大多数目标患者无法获得根治性治疗，从而减缓了整体市场成长，并将盈利的商业性机会限制在富裕阶层或享受高额医疗补贴的少数群体中。

市场趋势

由于红血球成熟促进剂的应用日益广泛，市场结构正在改变。这些药物能够改善红血球生成，并显着降低输血依赖性。这些生物製药针对红血球分化的后期阶段，为那些无法获得或合格接受根治性基因编辑疗法的患者提供了一种重要的缓解疾病治疗选择。随着医疗机构优先考虑治疗方法，这种临床转变正在推动显着的商业性成长。特别是，百时美施贵宝公司在其2025年10月发布的2025年第三季财报中指出，受血液疾病领域强劲需求的推动，Reblozyl®的全球销售额达到6.15亿美元，年成长31%。

同时，口服丙酮酸激酶活化剂的问世，也标誌着为各种地中海贫血基因型患者提供便利、非侵入性治疗方法的重大进展。这一趋势标誌着治疗方式从复杂的注射疗法转向小分子干预，这些小分子药物能够增强细胞代谢、改善血红蛋白稳定性并减少溶血。这些口服治疗方法的出现满足了α-地中海贫血和β-地中海贫血患者居家管理的一项重大未满足需求。作为此发展趋势的佐证，美国FDA于2025年12月核准了First-in-Class口服活化剂mitapivat上市。 Agios Pharmaceuticals在题为「FDA核准Agios的AQVESME」的新闻稿中宣布了这一消息，为输血依赖型和非输血依赖型地中海型贫血成人患者确立了新的治疗标准。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球地中海贫血治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗方法（铁螯合剂、输血、红系成熟促进剂、干细胞疗法等）
  • 依类型（α地中海贫血、β地中海贫血）
  • 依最终用户（医院、研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美地中海贫血治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲地中海贫血治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区地中海贫血治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲地中海贫血治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲地中海贫血治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球地中海贫血治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bluebird Bio, Inc.
• Merck & Co., Inc.
• Novartis AG
• ApoPharma Inc.
• Pfizer, Inc.
• Celgene Corporation
• Takeda Pharmaceuticals Company Limited
• Incyte Corporation
• Bellicum Pharmaceuticals
• GSK plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Thalassemia Treatment Market is projected to expand from USD 923.81 Million in 2025 to USD 1456.22 Million by 2031, registering a CAGR of 7.88%. Treatment modalities encompassed within this sector include chronic blood transfusions, iron chelation therapies, bone marrow transplants, and emerging gene therapies. Growth is largely propelled by the increasing global incidence of genetic blood disorders and the integration of curative interventions like gene editing technologies. Additionally, the market is being bolstered by the broadening of government-backed screening initiatives and the regulatory approval of innovative therapeutic agents, alongside strong pipeline developments aiming to lower transfusion dependency in beta-thalassemia patients.

Despite this progress, widespread adoption is hindered by the exorbitant costs of new therapies and the logistical complexities associated with chronic transfusion protocols. Securing a consistent and safe blood supply remains a major operational challenge in numerous regions. For instance, the Thalassemia International Federation noted that in 2025, over 75 percent of patients in low- and middle-income nations faced blood insufficiency. Such disparities in resource availability continue to create significant hurdles for market accessibility and the equitable distribution of treatments on a global scale.

Market Driver

The commercialization of curative gene editing therapies is fundamentally transforming the Global Thalassemia Treatment Market by shifting the focus from chronic management to potential functional cures. This evolution is driven by the approval and deployment of high-value ex vivo gene therapies targeting the genetic roots of transfusion-dependent beta-thalassemia, which are securing significant market value and traction in specialized centers. For example, in its "Third Quarter 2024 Results" from November 2024, Bluebird Bio reported 57 patient starts across its commercial portfolio year-to-date, with 35 attributed to the beta-thalassemia therapy Zynteglo. Reinforcing this financial maturation, Vertex Pharmaceuticals announced in its "Q3 2024 Financial Results" in November 2024 that it had generated its first commercial revenue of $2 million from the gene editing therapy Casgevy.

Concurrently, the increasing global prevalence of thalassemia and hemoglobinopathies maintains strong demand for both innovative therapeutics and supportive care regimens. As diagnostic capabilities enhance and demographics shift, the patient population requiring lifelong care is growing, especially in regions with high concentrations of genetic traits. According to the "Global Map of Evidence and Gaps" review released by the Thalassemia International Federation in January 2025, roughly 300,000 children are born annually with hemoglobinopathies worldwide, highlighting the urgent need for scalable treatments. This expanding disease burden necessitates substantial healthcare investment, ensuring that while gene therapies occupy the premium market segment, the foundational demand for iron chelation and transfusion infrastructure remains a crucial volume driver.

Market Challenge

The prohibitive costs associated with novel gene therapies constitute a major restraint on the growth of the Global Thalassemia Treatment Market. While these advanced interventions offer curative possibilities, their pricing structures impose severe financial strain on healthcare payers and reimbursement frameworks. This economic pressure limits widespread adoption, as numerous private insurers and public health programs find it difficult to manage the substantial upfront expenditures these treatments require. As a result, the disparity between regulatory approval and actual patient access is widening, restricting revenue potential for manufacturers across both emerging and established markets.

This financial exclusivity creates significant barriers to equitable access, as evidenced by current industry pricing. The Thalassemia International Federation reported in 2025 that the average acquisition cost for a single administration of an approved gene editing therapy exceeded USD 2.1 million per patient. Such a pricing barrier effectively precludes a large portion of the target population from obtaining curative care, thereby slowing the market's overall growth trajectory and limiting lucrative commercial opportunities to a narrow demographic within wealthy or heavily subsidized healthcare systems.

Market Trends

The market is being reshaped by the increasing adoption of erythroid maturation agents, which address ineffective erythropoiesis to significantly lower transfusion dependency. These biologic therapies target the late stages of red blood cell differentiation, providing a vital disease-modifying option for patients who are unable to access or are ineligible for curative gene editing. This clinical shift is driving substantial commercial growth as providers prioritize treatments that reduce the logistical demands of chronic transfusions; notably, Bristol Myers Squibb reported in its "Third Quarter 2025 Financial Results" in October 2025 that global revenues for Reblozyl rose 31 percent year-over-year to $615 million, fueled by robust demand in hematology.

In parallel, the introduction of oral pyruvate kinase activators signifies a key advancement in providing accessible, non-invasive therapies for various thalassemia genotypes. This trend moves away from complex injectable regimens toward small-molecule interventions that boost cellular metabolism to enhance hemoglobin stability and decrease hemolysis. The availability of these oral options fulfills a significant unmet need for convenient, home-based management for both alpha- and beta-thalassemia patients. A testament to this evolution occurred in December 2025, when Agios Pharmaceuticals announced in the press release "FDA Approves Agios' AQVESME" that the U.S. FDA had approved mitapivat, the first-in-class oral activator, setting a new therapeutic standard for adults with transfusion-dependent and non-transfusion-dependent thalassemia.

Key Market Players

• Bluebird Bio, Inc.
• Merck & Co., Inc.
• Novartis AG
• ApoPharma Inc.
• Pfizer, Inc.
• Celgene Corporation
• Takeda Pharmaceuticals Company Limited
• Incyte Corporation
• Bellicum Pharmaceuticals
• GSK plc

Report Scope

In this report, the Global Thalassemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thalassemia Treatment Market, By Treatment

• Iron Chelating Drugs
• Blood Transfusions
• Erythyroid Maturation Agents
• Stem Cell Therapy
• Others

Thalassemia Treatment Market, By Type

• Alpha Thalassemia
• Beta Thalassemia

Thalassemia Treatment Market, By End User

• Hospitals
• Research Institutes
• Others

Thalassemia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thalassemia Treatment Market.

Available Customizations:

Global Thalassemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thalassemia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Iron Chelating Drugs, Blood Transfusions, Erythyroid Maturation Agents, Stem Cell Therapy, Others)
  • 5.2.2. By Type (Alpha Thalassemia, Beta Thalassemia)
  • 5.2.3. By End User (Hospitals, Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Thalassemia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Thalassemia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Thalassemia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Thalassemia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End User

7. Europe Thalassemia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Thalassemia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Thalassemia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Thalassemia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Thalassemia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Thalassemia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Thalassemia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Thalassemia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Thalassemia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Thalassemia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Thalassemia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Thalassemia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Thalassemia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Thalassemia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Thalassemia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Thalassemia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User

10. South America Thalassemia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Thalassemia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Thalassemia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Thalassemia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Thalassemia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bluebird Bio, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Novartis AG
• 15.4. ApoPharma Inc.
• 15.5. Pfizer, Inc.
• 15.6. Celgene Corporation
• 15.7. Takeda Pharmaceuticals Company Limited
• 15.8. Incyte Corporation
• 15.9. Bellicum Pharmaceuticals
• 15.10. GSK plc

16. Strategic Recommendations

17. About Us & Disclaimer